We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Offers Endpoints for Tuberculosis Clinical Trials
FDA Guidance Offers Endpoints for Tuberculosis Clinical Trials
November 11, 2013
Sponsors designing clinical trials for drugs or multi-drug regimens for treatment of tuberculosis should focus on one of three endpoints.